Key result
Severe frailty was associated with increased mortality (HR 6.26; 95% CI 2.32-16.90), but recovery to a nonfrail state reduced the risk of the primary composite endpoint (RR 0.53; 95% CI 0.36-0.79).
Why the study?
Frailty is common in advanced HF and influences durable LVAD decisions, but its prevalence, prognostic significance, and reversibility with contemporary LVAD therapy needed characterization.
Does baseline frailty severity predict adverse outcomes and is it reversible in advanced heart failure patients receiving LVAD therapy?
Cohort (n=2,724)
Yes
Does baseline frailty severity predict adverse outcomes and is it reversible in advanced heart failure patients receiving LVAD therapy?
Frailty is highly prevalent but often dynamic and partially reversible after LVAD implantation, suggesting it may reflect physiological vulnerability rather than irreversible decline.
Answers are grounded in this paper and cite their sources.
Frailty assessment may refine LVAD risk stratification in advanced HF; leaves open whether targeted reversal strategies improve survival.
BACKGROUND Frailty is common in advanced heart failure (HF) and influences decisions regarding durable left ventricular assist device (LVAD) therapy. OBJECTIVES This study aims to characterize the prevalence, prognostic significance, and reversibility of frailty in patients receiving contemporary LVAD therapy. METHODS Pooled analysis of HeartMate 3 LVAD recipients from the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) trial portfolio and ARIES-HM3 (Antiplatelet Removal and Hemocompatibility Events with the HeartMate 3 Pump) trial. Frailty was quantified using the Rockwood cumulative deficit score and defined as a frailty index (FI) ≥0.21. The authors further stratified frail participants into tertiles of increasing frailty: mildly frail (FI: 0.21-0.324), moderately frail (FI: 0.325-0.39), and severely frail (FI: ≥0.40). The primary outcome was a composite of death, hemocompatibility-related adverse events, renal dysfunction, or right HF. RESULTS Among 2,724 LVAD recipients, 95% met criteria for frailty at baseline. Increasing frailty severity was associated with progressively higher risk of the primary composite outcome and a >6-fold increase in mortality in the most severely frail group than in nonfrail patients (HR: 6.26; 95% CI: 2.32-16.90). Frailty improved substantially after LVAD implantation, with the greatest absolute reductions observed among patients with severe baseline frailty. Recovery to a nonfrail state occurred in 15% of patients by 3 months and was associated with significantly lower subsequent risk of the primary endpoint (rate ratio: 0.53; 95% CI: 0.36-0.79). A multivariable model predicted recovery from frailty with good discrimination (area under the curve: 0.78-0.81). CONCLUSIONS Frailty is highly prevalent among patients undergoing LVAD implantation but is often dynamic and partially reversible after restoration of circulatory support. In advanced HF, frailty may reflect physiological vulnerability related to circulatory insufficiency rather than irreversible decline and may represent a modifiable risk state when evaluating candidates for durable mechanical circulatory support.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in advanced heart failure (HF) (n=2,724). Frailty vs. Nonfrail patients was evaluated on composite of death, hemocompatibility-related adverse events, renal dysfunction, or right HF (Rate ratio 0.53, 95% CI 0.36-0.79). Severe frailty was associated with increased mortality (HR 6.26; 95% CI 2.32-16.90), but recovery to a nonfrail state reduced the risk of the primary composite endpoint (RR 0.53; 95% CI 0.36-0.79).
Synapse has enriched 10 related papers. Consider them for comparative context: